2
Clinical Trials associated with Anti-GPC3 chimeric antigen receptor T cell therapy(Shanghai Genechem Co., Ltd.)An Open-label, Uncontrolled, Single-arm Pilot Study to Evaluate Intratumor Injection Mediated GPC3-targeted Chimeric Antigen Receptor T Cells in Advanced Hepatocellular Carcinoma
In this study, CART cells are targeted to GPC3 by intratumor injected that we hope by this means could improve the local CAR-T cell numbers, meanwhile reduce the potential side effects.
A Single-arm Pilot Clinical Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy
The purpose of this study is to collect the date on the safety and potential effectiveness of CART cells combined with interventional therapy in patients with advanced liver malignancy.
100 Clinical Results associated with Anti-GPC3 chimeric antigen receptor T cell therapy(Shanghai Genechem Co., Ltd.)
100 Translational Medicine associated with Anti-GPC3 chimeric antigen receptor T cell therapy(Shanghai Genechem Co., Ltd.)
100 Patents (Medical) associated with Anti-GPC3 chimeric antigen receptor T cell therapy(Shanghai Genechem Co., Ltd.)
100 Deals associated with Anti-GPC3 chimeric antigen receptor T cell therapy(Shanghai Genechem Co., Ltd.)